Syndicate Feeds
HIVandHepatitis.com High Rate of Sustained Response with Interferon-Free Daclatasvir + Asunaprevir for HepC HCV: http://t.co/L5oOdO0tWednesday, 25 January 2012 11:08
Wednesday, 25 January 2012 11:07
High Rate of Sustained Response with Interferon-Free Daclatasvir + Asunaprevir for Hepatitis C
A dual oral regimen of Bristol-Myers Squibb's hepatitis C virus (HCV) protease inhibitor asunaprevir (formerly BMS-650032) and HCV NS4A inhibitor daclatasvir (BMS-790052) cleared the virus in one-third of genotype 1 prior null responders to prior interferon-based therapy, and both of those with genotype 1b, according to data published in the January 19, 2012, New England Journal of Medicine .
HIV/AIDS
FDA Approves New Tenofovir (Viread) Formulation and Dosing Regimen for HIV+ Children
The U.S. Food and Drug Administration (FDA) and Gilead Sciences last week announ...
Congress Reinstates Federal Funding Ban on Needle Exchange
House Republican legislators added language banning federal funding of needle an...
Oral HIV Tests May Be Less Accurate than Blood Tests
Oral HIV antibody testing is quick and convenient, but this method is not quite ...
Companies Lower HIV Drug Prices for ADAP, but Many Patients Still Waiting
Four pharmaceutical companies recently agreed to discount their prices on antire...
Hepatitis B
Do Not Use Telbivudine (Tyzeka) with Pegasys for Hepatitis B, FDA Warns
The U.S. Food and Drug Administration (FDA) last week announced revisions to the...
CDC Advisory Committee Recommends Hepatitis B Vaccine for People with Diabetes
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immun...
Interpreting Hepatitis B Tests
The following table from the U.S. Centers for Disease Control and Prevention (CD...
Hepatitis B and C Are Major Causes of Liver Cancer in U.S.
Chronic hepatitis C infection has replaced alcohol-related cirrhosis as a major ...
Hepatitis C
Achillion, Presidio, Idenix Announce HCV Drug Pipeline Developments
Three companies developing direct-acting antiviral agents (DAAs) for hepatitis C...
Experimental Hepatitis C Vaccine Triggers T-Cell Responses in Early Clinical Trial
An investigational adenovirus-based hepatitis C virus (HCV) vaccine induced sust...
AASLD: HCV Screening of 1945-1965 Birth Cohort Appears Cost-Effective
Screening all people in the U.S. in the 46 to 66 year age group for hepatitis C ...
Anemia during Hepatitis C Treatment Predicts Sustained Response to Pegylated Interferon/ribavirin
Hepatitis C patients who develop anemia during treatment with pegylated int...
Coinfection
HIV/HBV Coinfection Raises Risk of AIDS Progression and Death
Coinfection with hepatitis B virus (HBV) nearly doubled the risk of progression ...
AASLD: Upping Ribavirin Dose Does Not Increase Interferon Effectiveness in HIV/HCV Coinfected Patients
Starting hepatitis C treatment with a double dose of ribavirin plus erythropoiet...
Other Infections
New Shorter Treatment for Latent TB Not Recommended for HIV+ People on ART
Expert panels that put together the Department of Health and Human Services anti...
STD Report Shows Small Rise Overall, Higher Rates for People of Color, Young Gay Men
Reported cases of gonorrhea rose slightly and syphilis declined somewhat during ...
Rising Rate of Mouth and Throat Cancers Caused by HPV
Oral cancers caused by oncogenic human papillomavirus (HPV) -- the same virus th...
Ribavirin May Be Effective against Acute Hepatitis E
Ribavirin, a component of standard therapy for chronic hepatitis C, may also be ...
Subscribe To Our Newsletter
Sign up for our free twice-weekly e-newsletter
CONTINUING MEDICAL EDUCATION
CONFERENCE COVERAGE
The Liver Meeting (AASLD 2011)
November 4-8, 2011, San Francisco
|
49th Annual Meeting of the Infectious Disease Society of America (IDSA 2011) |
|
|
13th European AIDS Conference (EACS 2011) |
|
|
51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) |
|
|
6th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2011) |
|
|
|
46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011) March 30-Apr. 3, 2011, Berlin |
|
|
18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) |
|
|
The Liver Meeting (AASLD 2010) October 29-Nov. 3, 2010, Boston |
|
|
50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) September 12-15, 2010, Boston |
|
|
XVIII International AIDS Conference (AIDS 2010) July 18-23, 2010, Vienna |
